Study to Demonstrate Non-Inferior Efficacy and Safety of CinnoRA® Versus Humira® for Treatment of Active RA
A Phase III, Randomized, Two-armed, Double-blind, Parallel, Active Controlled Clinical Trial to Determine the Non-inferior Efficacy and Safety of CinnoRA® (Adalimumab, CinnaGen Co.) Versus Humira® for Treatment of Active RA
Sponsor: Cinnagen
Listed as NCT03172325, this PHASE3 trial focuses on Active Rheumatoid Arthritis and remains completed. Sponsored by Cinnagen, it has been updated 7 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Mar 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Mar 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jul 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Nov 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cinnagen
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Isfahan, Iran
- • Kerman, Iran
- • Mashhad, Iran
- • Rasht, Iran
- • Shahr-e Kord, Iran
- • Shiraz, Iran
- • Tabriz, Iran
- • Tehran, Iran